Table 3 Summary of PK parameters at day 14 (PK population)

From: A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

 

GSK3036656 (ganfeborole)

   

PK parameter

1 mg

5 mg

15 mg

30 mg

 

n = 8

n = 14

n = 14

n = 13

AUC0−24 (ng*h/ml), geometric mean (% CVb)

282.1 (25.8)

1,497.1 (12.4)

4,493.9 (12.5)

11,540.0 (17.8)

Cmax (ng/ml), geometric mean (% CVb)

16.93 (23.7)

94.60 (24.7)

291.41 (18.9)

705.24 (20.2)

Tmax (h), median (range)

1.50 (0.50, 6.00)

2.49 (0.50, 4.00)

1.00 (0.50, 4.00)

2.00 (0.50, 8.00)

  1. All GSK3036656 (ganfeborole) cohorts received a loading dose on day 1.
  2. AUC0–24, area under the plasma concentration–time curve from treatment initiation to 24 h; Cmax, maximum concentration; CVb, inter-subject variability; PK, pharmacokinetics; Tmax, time to the maximum concentration.
Back to article page